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Background: HAGE protein is a known immunogenic cancer-specific antigen.
Methods: The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three
cohorts of patients with BC (n¼ 2147): early primary (EP-BC; n¼ 1676); primary oestrogen receptor-negative (PER-BC; n¼ 275)
treated with adjuvant anthracycline-combination therapies (Adjuvant-ACT); and primary locally advanced disease (PLA-BC) who
received neo-adjuvant anthracycline-combination therapies (Neo-adjuvant-ACT; n¼ 196). The relationship between HAGE
expression and the tumour-infiltrating lymphocytes (TILs) in matched prechemotherapy and postchemotherapy samples were
investigated.
Results: Eight percent of patients with EP-BC exhibited high HAGE expression (HAGEþ ) and was associated with aggressive
clinico-pathological features (Pso0.01). Furthermore, HAGEþ expression was associated with poor prognosis in both univariate
and multivariate analysis (Pso0.001). Patients with HAGEþdid not benefit from hormonal therapy in high-risk ER-positive disease.
HAGEþ and TILs were found to be independent predictors for pathological complete response to neoadjuvant-ACT; Po0.001.
A statistically significant loss of HAGE expression following neoadjuvant-ACT was found (P¼ 0.000001), and progression-free
survival was worse in those patients who had HAGEþ residual disease (P¼ 0.0003).
Conclusions: This is the first report to show HAGE to be a potential prognostic marker and a predictor of response to ACT in
patients with BC.
Breast cancer (BC) is the most common and leading cause of
cancer deaths in women. Despite the improved outcomes which
have been achieved by earlier detection and recent advances in
therapy, recurrence still occurs in over 20% of patients (Early
Breast Cancer Trialists’ Collaborative Group et al, 2008; Dotan and
Goldstein, 2010; Gluck and Mamounas, 2010). It is therefore
becoming increasingly important to identify biomarkers that can
aid in assessing a patient’s risk and response to therapy and which
might also act as novel targets for immunotherapies (Harris et al,
2007; Harbeck et al, 2010). Although identifying tumour-associated
antigens that induce adaptive Tcell immunity is a prerequisite for
establishing effective immunotherapy strategies, there is currently a
lack of suitable candidates for the development of such treatments
in BC (Mathieu et al, 2007).
The helicase antigen known as HAGE was first identified in a
sarcoma cell line using representational difference analysis
(Martelange et al, 2000). HAGE was subsequently shown to be
expressed in many haematological and solid tumour samples but
not in any of the normal tissues tested, except testis (Martelange
et al, 2000; Adams et al, 2002; Mathieu et al, 2010) – it was
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therefore classified as a Cancer Testes Antigen (CTA). We have
previously reported that HAGE protein is required for the
proliferation of cancer cells and that it is immunogenic (Adams
et al, 2002; Mathieu et al, 2007).
To date, the clinico-pathological and prognostic significance of
HAGE expression in BC remains unknown. We have therefore
assessed the clinico-pathological and prognostic and predictive
significance of HAGE expression in BC using three well-
characterized cohorts of patients (n¼ 2147).
PATIENTS AND METHODS
Study populations. Consent was obtained from all the patients as
per hospital’s Standard of Care. This included a clause which
permitted the use of excess tissue in research projects that had been
approved by both the Local Research Committee and the Hospital
Research and Innovations Department.
All work was conducted under the study ‘Development of a
molecular genetic classification of breast cancer’ and approved by
the Nottingham Research Ethics Committee (Ref: C1080301) and
the Hospital Research and Innovations Department (Ref: 03HI01).
Early primary BC (EP-BC) cohort. The study was performed in a
1676 consecutive series of patients with primary invasive BC who
were diagnosed between 1986 and 1999 (Elston and Ellis, 1991;
Pinder et al, 1994). Patients received standard surgery (mastectomy
or wide local excision) with radiotherapy. Before 1989, patients did
not receive either endocrine or chemotherapy. After 1989,
adjuvant-therapy was scheduled on the basis of the Nottingham
Prognostic Index (NPI), oestrogen receptor-a (ER-a) and meno-
pausal status. Patients with NPI scoreso3.4 (low risk) did not
receive adjuvant-therapy. Premenopausal patients with NPI
scoresX3.4 (high risk) received cyclophosphamide, Methotrexate
and 5-Flourouracil (CMF) combination chemotherapy, and
patients with ER-a-positive tumours were also offered Tamoxifen
for 5 years. The minimum follow-up period was 123 months. Data
were randomised into two equal cohorts using a double random
number sort. Alternate cases were put into a training set (n¼ 838)
and a test set (n¼ 838). Both cohorts were balanced with regards to
HAGE expression, primary clinicopathological features, treatment
and survival outcome (Supplementary Table S1).
Primary ER-negative BC (PER-BC). In order to evaluate the
value of HAGE protein expression as a biomarker in the context of
current combination cytotoxic chemotherapy, we also analysed its
expression in an independent series of 275 patients with PER-BC
who had been diagnosed and managed at the same institution
between 1999 and 2007, 141 of whom were treated with adjuvant-
ACT. Comprehensive follow-up data were available
for 275 patients (median¼ 89 months, mean¼ 86 months;
Supplementary Table S2).
Primary locally advanced BC (PLA-BC). Tumour-infiltrating
lymphocytes (TILs) and HAGE expression were evaluated in pair-
matched prechemotherapy core biopsies and postchemotherapy
surgical specimens from 196 female patients with PLA-BC (stage
IIIA-C) treated with neoadjuvant-ACT, and their relationship(s)
with response to treatment and survival were investigated. These
patients were diagnosed by needle core biopsy at the Nottingham
University City Hospital between 1996 and 2010. A pathological
complete response (pCR) was defined as the absence of any
residual invasive carcinoma at both the primary site and in axillary
lymph nodes (LNs). On average, 16 breast-blocks and all submitted
LNs were examined for each case before a diagnosis of pCR was
reached. Detailed patient demographics and clinico-pathological
characteristics were routinely assessed and regularly updated
(Supplementary Table S3).
Pathology assessment of TILs. Histopathological analysis of the
TILs was performed on haematoxylin and eosin–stained sections
adopting the protocol by Denkert et al (2010). In summary,
intratumoral lymphocytes (iTu-Ly) were defined as intraepithelial
mononuclear cells within tumour cell nests or in direct contact
with tumour cells and were reported as the percentage of the
tumour epithelial nests that contain infiltrating lymphocytes.
Stromal lymphocytes (str-Ly) were defined as the percentage of
tumour stroma area that contains a lymphocytic infiltrate without
direct contact to tumour cells. Histopathological analysis was
performed by two pathologists (TAF and IOE) who were blinded
to clinical and response data; the mean was used for analysis. TILs
was classified into three categories: (1) TILs predominant infiltrate
defined as the presence of either intratumoral lymphocytes
in460% of tumour cell nests or lymphocytes in460% of the
stromal area, (2) focal TILs infiltrate included detectable mono-
nuclear cells410% but o60% of str-Ly or iTu-Ly and (3) no or
minimal TILs defined as no detectable or presence of p10%
mononuclear cells in tumour cell nests and tumour stroma.
Survival data. Survival data, including survival time, disease-free
survival (DFS) and development of loco-regional and distant
metastases (DM), were maintained on a prospective basis. DFS was
defined as the number of months from diagnosis to the occurrence
of recurrence or DM relapse. BC-specific survival (BCSS) was
defined as the number of months from diagnosis to the occurrence
of BC-related death. Survival was censored if the patient was still
alive, lost to follow-up or died from other causes. The Reporting
Recommendations for Tumor Marker Prognostic Studies
(REMARK) criteria (McShane et al, 2005) were followed through-
out this study.
Tissue microarrays (TMAs) and immunohistochemistry (IHC).
Tumours from both EP-BC and PER-BC cohorts, as well as
postsurgical specimens from patients with PLA-BC, were incorpo-
rated into TMAs. These were constructed using six replicate
0.6-mm cores from the centre and periphery of the tumours of
each patient. In addition, full-face sections from the diagnostic
prechemotherapy core biopsy were used for those PLA-BC cases
that were treated with neoadjuvant-ACT. The TMAs and full-face
sections were IHC profiled using antibodies for HAGE and other
antibodies (Supplementary Table S4), as previously described
(Abdel-Fatah et al, 2010a, b). IHC staining was performed using a
Novolink Detection kit according to the manufacturer’s protocol
(Leica Microsystems, Wetzlar, Germany). For this, sections were
incubated overnight at 4 1C with 1/175 dilution of custom-made
rabbit anti-HAGE mono-specific polyclonal antibody (Mathieu
et al, 2010). The IHC was validated using a commercially available
antibody that was developed and validated as part of the Human
Protein Atlas (HPA) project (anti-DDX43; HPA031381, Sigma-
Aldrich, St Louis, MO, USA); in this case, sections were incubated
overnight at 4 1C at 1/100 dilution (Supplementary Figure S1).
Expression of HER2, ER and PR was assessed according
to the American Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) guidelines (Wolff et al, 2007; Hammond
et al, 2010).
To validate the use of TMAs for immuno-phenotyping, full-face
sections of 40 cases were stained, and the protein expression levels were
compared. The concordance between TMAs and full-face sections was
excellent using Cohen’s kstatistical test for categorical variables
(k¼ 0.8). Positive and negative (omission of the primary antibody
and IgG-matched serum) controls were included in each run.
Evaluation of HAGE immunohistochemical staining. Tumour
cores were evaluated by two pathologists (co-authors: TAF, IOE)
who were blinded to the clinico-pathological characteristics of
patients in two different settings. Whole-field inspection of the
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core was scored, and intensities of both nuclear and cytoplasmic
staining were grouped as follows: 0¼ no staining, 1¼weak
staining, 2¼moderate staining, and 3¼ strong staining. The
percentage of each category was estimated and due to intratumoral
and intertumoral heterogeneity of the staining, the average
percentage among six cores was calculated and high HAGE
(HAGEþ ) expression was defined as the presence of strong
cytoplasmic and/or nuclear staining in 410% of malignant cells
(Figure 1A). Intraobserver (k40.8; Cohen’s k test) and inter-
observer (k40.8; using multi-rater k tests) observer agreements
were excellent. In cases where discordant results were obtained, the
slides were re-evaluated by both pathologists together, and a
consensus was reached.
Statistical analysis. Data analysis was performed by (TAF, GRB
and SYC) who were blinded to clinical and response data using
SPSS (Version 17, Chicago, IL, USA). Where appropriate,
Pearson’s Chi-square and Student’s tests were used. Positivity for
HAGE protein both before and after chemotherapy was calculated
and compared using McNemar’s test. Significance was defined at
Po0.05.
Cumulative survival probabilities were estimated using the
Kaplan–Meier method, and the differences between survival rates
were tested for significance using the log-rank test. Multivariate
analysis for survival was performed using the Cox proportional
hazard model. The proportional hazards assumption was tested
using standard log–log plots. Hazard ratios (HRs) and 95%
confidence intervals (95% CIs) were estimated for each variable. All
tests were two-sided with a 95% CI, and a P-valueo0.05 was
considered to be indicative of statistical significance. A stringent
P-valueo0.01 was considered to indicate statistical significance for
multiple comparisons.
RESULTS
EP-BC patient group – training set (n¼ 838)
Clinico-pathological significance of HAGE expression. Eight
percent (69 out of 838) of tumours examined were found to be
positive for HAGE expression (HAGEþ ; Figure 1A). In invasive
BC, HAGEþ expression was significantly associated with aggres-
sive and adverse pathological features (Table 1), including high
grade, absence of hormonal receptors (ER /PR ), absence of the
anti-apoptotic Bcl2 (Bcl2 ), presence of the triple-negative
phenotype (TNBC) and overexpression of HER2 (HER2þ ).
Interestingly, none of the invasive lobular carcinomas were
HAGEþ (0 out of 69).
Clinical outcome of the training set
(B-1) Whole set (B-2) Lymph node negative (B-3)ER + endocrine therapy (B-4) High-risk ER–
HAGE– (n = 763)
HAGE+ (n = 68)
Log rank = 20.1, P = 0.0000007
HAGE– (n = 763)
HAGE+ (n = 68)
Log rank = 13.6, P = 0.0002
HAGE– (n = 482)
HAGE+ (n = 43)
Log rank = 30.3, P = 4×10–8
HAGE– (n = 482)
HAGE+ (n = 43)
Log rank = 16.5, P = 0.00005
HAGE– (n = 166)
HAGE+ (n = 26)
Log rank = 8.0, P = 0.005
HAGE– (n = 166)
HAGE+ (n = 26)
Log rank = 4.4, P = 0.037
HAGE– (n = 197)
HAGE+ (n = 14)
Log rank = 5.7, P = 0.017
HAGE– (n = 197)
HAGE+ (n = 14)
Log rank = 1.7, P = 0.198
Disease-free survival (months)
Breast cancer-specific survival (months) Breast cancer-specific survival (months) Breast cancer-specific survival (months) Breast cancer-specific survival (months)
Disease-free survival (months) Disease-free survival (months) Disease-free survival (months)
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Figure 1. The clinical outcome of HAGE protein expression in the training set of primary early breast cancer. (A) (1–3) Photomicrographs showing weak
nuclear expression of HAGE in normal breast tissue (A-1), breast cancer tissue (A2–3) showing negative expression of HAGE in neoplastic cells
(A-2), positive expression of HAGE in neoplastic cells (A-3) (magnification 200). (B) (1–4) Kaplan–Meier curves showing the relationship between
HAGE expression and breast cancer-specific and disease-free survival in the training set of primary early breast cancer (PE-BC). See text for details.
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Table 1. Clinico-pathological characteristics of HAGE protein expression in the discovery and test sets
Discovery set (n¼838), n (%) Test set (n¼838)
Variables
HAGE-negative
(n¼769)
HAGE-positive
(n¼69)
Adjusted
P-value
HAGE-negative
(n¼769)
HAGE-positive
(n¼69)
Adjusted
P-value
Pathological parameters
Tumour size
T1 aþb (p1.0) 87 (11.4) 3 (4.3) 90 (11.7) 5 (7.2)
T1 c (41.0–2.0) 395 (51.8) 38 (55.1) 0.1 378 (49.3) 37 (53.6) 0.693
T2 (42.0–5.0) 255 (33.5) 28 (40.6) 283 (36.9) 26 (37.7)
T3 (45) 25 (3.3) 0 (0) 15 (2.0) 1 (1.4)
Lymph node stage
Negative 484 (63.4) 44 (63.8) 0.642 474 (61.7) 43 (62.3) 0.87
Positive (1–3 nodes) 211 (27.7) 21 (30.4) 228 (29.7) 19 (27.5)
Positive (43nodes) 68 (8.9) 4 (5.8) 66 (8.6) 7 (10.1)
Tumour type
IDC-NST 385 (58.6) 42 (66.7) 367 (55.4) 41 (66.1)
Medullary/atypical 12 (1.8) 1 (1.6) 0.052 19 (2.9) 2 (3.2) 0.074
Tubular carcinoma 138 (21.0) 14 (22.2) 133 (20.1) 14 (22.6)
Invasive lobular carcinoma 81 (12.3) 0 (0) 73 (11.0) 0 (0)
Others 41 (6.2) 6 (9.5) 70 (10.6) 5 (8.1)
Tumour gradea
G1 138 (18.1) 11 (15.9) 0.001b 140 (18.3) 5 (7.2) 0.002b
G2 268 (35.2) 11 (15.9) 267 (34.9) 17 (24.6)
G3 356 (46.7) 47 (68.1) 359 (46.9) 47 (68.1)
Hormonal receptors
Oestrogen receptor
Negative 186 (25.1) 28 (40.6) 0.005b 176 (23.2) 31 (46.3) 0.00003b
Positive 556 (74.9) 41 (59.4) 581 (76.8) 36 (53.7)
Progesterone receptor
Negative 295 (41.5) 39 (56.5) 0.016b 273 (38.1) 40 (58.8) 0.001b
Positive 416 (58.5) 30 (43.5) 444 (61.9) 28 (41.2)
Androgen receptor
Negative 210 (35.2) 24 (42.1) 0.301 221 (37.0) 23 (36.5) 0.936
Positive 386 (64.8) 33 (57.9) 376 (63.0) 40 (63.5)
Proliferation/cell cycle regulators
Mitotic index
M1 (low; mitoses o10) 298 (39.4) 14 (20.3) 0.002b 288 (38.0) 10 (14.5) 0.0003b
M2 (medium; mitoses 10–18) 140 (18.5) 12 (17.4) 142 (18.7) 14 (20.3)
M3 (high; mitoses418) 318 (42.1) 43 (62.3) 328 (43.3) 45 (65.2)
Ki67
Negative 241 (38.7) 16 (23.2) 0.011b 249 (38.7) 17 (25.0) 0.027b
Positive 382 (61.3) 53 (76.8) 395 (61.3) 51 (75.0)
KIF2C
Negative 218 (42.7) 9 (20.0) 0.003b 203 (38.7) 9 (17.0) 0.002b
Positive 292 (57.3) 36 (80.0) 322 (61.3) 44 (83.0)
SPAG5
Negative 482 (80.7) 38 (66.7) 0.012b 494 (82.9) 37 (66.1) 0.004b
Positive 115 (19.3) 19 (33.3) 102 (17.1) 19 (33.9)
TOP2A
Negative 251 (46.2) 23 (46.0) 0.976 254 (47.6) 19 (33.9) 0.066
Positive 292 (53.8) 27 (54.0) 280 (52.4) 37 (66.1)
P16
Negative 460 (87.1) 41 (82.0) 0.308 455 (87.7) 40 (71.4) 0.002b
Positive 68 (12.9) 9 (18.0) 64 (12.3) 16 (28.6)
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HAGE and other biomarkers of cell cycle and mitosis. HAGEþ
was significantly associated with high mitotic index (MI,
P¼ 0.002), and high levels of Ki67 (Ki67þ ; P¼ 0.01), KIF2C
(KIF2Cþ ; P¼ 0.003) and SPAG5 (SPAG5þ ; P¼ 0.01) expres-
sion. In the multivariate logistic analysis, high MI (OR (95% CI);
1.5 (1.10–1.98), P¼ 0.018) and low Bcl2 expression (OR (95% CI);
0.33 (0.20–0.56), Po0.0001) were independent predictors for
HAGEþ expression.
Survival analyses. In the whole cohort (n¼ 838), HAGEþ
expression was associated with adverse clinical outcomes at 10
years, with a significant increase in the risk of death (Po0.0001)
(Figure 1(B-1)) and recurrence (P¼ 0.0002) compared with
HAGE tumours. Exploring the clinical outcome of patient
subgroups with early-stage tumours (Figure 1(B-2)), ERþ tumours
(Figure 1(B-3)) or patients bearing ER tumours (Figure 1(B-4))
confirmed that patients with HAGEþ tumours exhibited a worse
prognosis than those patients with tumours expressing low levels of
HAGE.
Multivariate Cox regression analysis. HAGE, LN-stage, tumour
size and Bcl2 were confirmed as powerful independent predictors
for both BCSS and DFS in a multivariate Cox regression model,
which included other validated traditional pathological prognostic
factors and other co-founders and controlled for endocrine and
chemotherapy (Po0.01) (Table 2).
EP-BC patient group – test set (n¼ 838)
Clinico-pathological significance of HAGE expression. Eight
percent (69 out of 838) of the tumours were HAGEþ , and 92%
(769 out of 838) tumours were HAGE . HAGEþ expression was
Table 1. ( Continued )
Discovery set (n¼838), n (%) Test set (n¼838)
Variables
HAGE-negative
(n¼769)
HAGE-positive
(n¼69)
Adjusted
P-value
HAGE-negative
(n¼769)
HAGE-positive
(n¼69)
Adjusted
P-value
P53/apoptosis pathways
P53
Negative 495 (80.9) 40 (70.2) 0.053 484 (79.5) 41 (73.2) 0.175
Positive 117 (19.1) 17 (29.8) 125 (20.5) 15 (26.8)
Bcl2
Negative 225 (32.9) 29 (45.3) 0.045b 221 (32.2) 38 (58.5) 0.00002b
Positive 459 (67.1) 35 (54.7) 466 (67.8) 27 (41.5)
Bax
Negative 309 (69.9) 25 (64.1) 0.45 316 (72.5) 20 (46.5) 0.0004b
Positive 133 (30.1) 14 (35.9) 120 (27.5) 23 (53.5)
HER2 Family
EGFR
Negative 465 (78.7) 39 (70.9) 0.183 486 (83.2) 39 (69.6) 0.011b
Overexpression 126 (21.3) 16 (29.1) 98 (16.8) 17 (30.4)
HER2
Negative 695 (90.4) 56 (81.2) 0.016b 676 (89.3) 54 (78.3) 0.006b
Overexpression 74 (9.6) 13 (18.8) 81 (10.7) 15 (21.7)
HER3
Negative 292 (48.4) 23 (46.9) 0.841 321 (52.7) 23 (44.2) 0.251
Overexpression 311 (51.6) 26 (53.1) 288 (47.3) 29 (55.8)
HER4
Negative 270 (43.9) 25 (50) 0.404 255 (42.0) 23 (41.8) 1
Overexpression 345 (56.1) 25 (50) 352 (58.0) 32 (58.0)
Others
Triple-negative phenotype
No 610 (81.7) 49 (71) 0.027b 629 (83.6) 46 (66.7) 0.0004b
Yes 137 (18.3) 20 (29) 123 (16.4) 23 (33.3)
Basal-like phenotype
No 599 (83.7) 51 (79.7) 0.414 626 (85.6) 46 (72.0) 0.004b
Yes 117 (16.3) 13 (20.3) 105 (14.4) 18 (28.0)
Abbreviations: Basal like¼ negative expression of both ER and HER2 and either positive expression of EGFR, cytokeratin 14 or cytokeratin 5/6; Bax¼BCL2-associated X protein; Bcl2¼B-cell
CLL/lymphoma 2; EGFR¼epidermal growth factor receptor; ER¼oestrogen receptor; HAGE¼ helicase antigen; HER2 (ERBB2)¼ v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian); HER3 (ERBB3)¼ v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), HER4 (ERBB4)¼human epidermal receptor 4,
IDC-NST¼ invasive ductal carcinoma – no special type; KIF2C¼ kinesin family member 2C; SPAG5¼ sperm-associated antigen 5, TOP2A¼ topoisomerase (DNA) II alpha.
aNottingham histological grading system.
bStatistically significant.
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significantly associated with high histological grade (P¼ 0.0002),
ER /PR (Po0.001), Bcl2 (Po0.0001), HER2þ (P¼ 0.006)
and TNBC (P¼ 0.0004) (Table 1). Statistical associations between
HAGEþ and high p16 (P¼ 0.002), high Bax (P¼ 0.0004), high
EGFR (P¼ 0.01) and the presence of basal-like characteristics
(P¼ 0.004) were observed in the test set but not in the training set,
which has been confirmed when the two sets were pooled together.
This observation could be due to the borderline imbalance between
the test and training sets regarding the expression of EGFR
(P¼ 050).
HAGE and other biomarkers of cell cycle and mitosis. HAGEþ
was significantly associated with high MI (Po0.001), and high
expression of Ki67 (P¼ 0.027), KIF2C (P¼ 0.002) and SPAG5
(P¼ 0.004).
Survival analyses. HAGEþwas found to be associated with
adverse clinical outcomes in the whole cohort (Figure 2A; n¼ 838),
as well as in subgroups that included the LN-negative patients
(Figure 2B), ERþ patients (Figure 2C) and ER subpopulations
(Figure 2D) (o0.01). HAGE, LN stage, tumour size and Bcl2 were
independent predictors for BCSS (Po0.01) and DFS (Po0.0001)
in multivariate Cox regression analysis (Table 2).
HAGE is a prognostic biomarker in low-risk (NPIp3.4)
BC patients. The expression of HAGEþ in low-risk (NPIp3.4)
BC patients who did not receive either endocrine or chemotherapy
was associated with twice the risk of death (HR (95% CI)¼ 1.8
(1.3–2.4), P¼ 0.001) and relapse (HR (95% CI)¼ 1.7 (1.3–2.1),
P¼ 0.000029).
HAGE is a prognostic biomarker in ER-positive BC patients. In
high-risk/ERþBC, HAGE was associated with an adverse outcome
at 10 years and an increased risk of death from BC (HR: 1.2; 95%
CI: 1.01–1.52; P¼ 0.045) and recurrence (HR: 1.4; 95% CI: 1.2–1.7;
P¼ 0.0001). When high risk/ERþBC patients were stratified
according to the status of hormone therapy, HAGEþ retained its
prognostic effect on DFS in patients who either received (HR: 1.4;
95% CI: 1. 1–1.8; P¼ 0.009) or did not receive hormonal therapy
(HR: 1.5; 95% CI: 1.2–1.8; P¼ 0.001), whereas it lost its prognostic
effect on BCSS in patients who did not receive hormonal therapy
(HR: 0.96; 95% CI: 0.6–1.4; P¼ 0.811).
HAGE could be a predictor of hormone therapy resistance. ERþ /
high-risk BC patients who were HAGE exhibited a prolonged
BCSS and DFS when they were exposed to hormone therapy,
compared with those who did not receive any hormone therapy
(Pso0.0001; Figure 3A). No benefit was derived from prescribing
hormone therapy for ERþ /high-risk BC patients with
HAGEþ (Figure 3B).
PER-BC patient group. HAGE was highly expressed in 10%
(27 out of 275) of the ER-negative cohort of patients with early
stage disease (Figure 4A; n¼ 275).
Relationship between HAGE expression and clinical outcome
in patients who received no anthracycline. Similar to our
Table 2. Multivariate Cox regression analysis in the discovery and test sets
BCSS at 10 years DFS at 10 years
Training set Test set Training set Test set
Variables HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
HAGE (high) 2 1.3–3.1 0.002* 1.9 1.3–2.9 0.002* 1.7 1.2–2.5 0.004* 2.5 1.8–3.5 1107*
Lymph node stage
Negative 1 0.002* 1 61010* 1 1.4106* 1 7106*
Positive (1–3 nodes) 1.3 0.9–1.9 1.7 1.2–2.5 1.2 0.9–1.6 1.3 0.9–1.7
Positive (43 nodes) 2.4 1.5–3.9 4.6 2.8–7.2 2.9 1.9–4.4 2.7 1.8–4.1
Grade
Low (G1) 1 0.754 1 0.839 1 0.744 1 0.117
Intermediate (G2) 1.3 0.6–2.8 1.1 0.5–2.3 0.8 0.5–1.3 1 0.6–1.5
High (G3) 1.5 0.5–4.1 0.9 0.3–2.5 0.9 0.4–1.8 0.6 0.3–1.2
Size (continuous) 1.3 1.1–1.5 0.002* 1 0.9–1.2 0.626 1.3 1.1–1.4 4.9105* 1 0.9–1.2 0.475
Mitotic index
M1 1 0.4 1 0.195 1 0.362 1 0.030*
M2 1.5 0.7–2.9 1.2 0.7–2.4 1.4 0.9–2.3 1 0.6–1.6
M3 1.8 0.8–4.3 1.9 0.9–4.2 1.5 0.8–3.0 1.8 1.0–3.3
Ki67 (high) 1.6 1.0–2.5 0.072 1.5 1.0–2.4 0.082 1.1 0.8–1.6 0.508 1.4 1.0–2.0 0.079
ER ( ) 2.7 1.2–5.9 0.015* 1.1 0.6–2.4 0.729 1.5 0.7–3.0 0.288 1 0.5–1.9 0.993
HER2 (þ ) 1.8 1.0–3.2 0.047* 1.4 0.8–2.5 0.243 1.2 0.7–2.2 0.473 1.1 0.6–1.8 0.829
Bcl2 ( ) 2 1.4–2.9 2104* 2.6 1.8–3.8 2107* 1.5 1.1–2.0 0.016* 2.3 1.7–3.1 5108*
Triple negative (Yes) 1.4 0.6–3.3 0.492 1 0.4–2.4 0.946 1 0.5–2.2 0.984 0.7 0.4–1.5 0.734
Endocrine therapy (Yes) 0.8 0.6–1.2 0.334 1 0.7–1.4 0.969 0.9 0.7–1.2 0.382 1 0.7–1.3 0.915
Chemotherapy (Yes) 0.7 0.5–1.1 0.089 1 0.6–1.5 0.879 0.8 0.6–1.1 0.122 0.9 0.6–1.2 0.479
Abbreviations: Bcl2¼B-cell CLL/lymphoma 2; BCSS¼breast cancer-specific survival; CI¼ confidence interval; DFS¼disease-free survival; ER¼oestrogen receptor; HAGE¼ helicase antigen;
HER2¼HER2 (ERBB2)¼ v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); HR¼ hazard ratio. M1¼ low; mitoseso10,
M2¼medium; mitoses 10–18, M3¼ high; mitoses418. *Statistically significant (Po0.05).
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observation in the whole cohort (Figure 4A), HAGEþ expression
in patients with high-risk ERBC who did not receive
chemotherapy or received less-effective CMF therapy (n¼ 134;
Figure 4B) was associated with adverse clinical outcomes at 5 years,
with a significant increase in the risk of death (P¼ 0.0005) and
recurrence (P¼ 0.0003) compared with HAGE tumours.
Relationship between HAGE expression and clinical outcome in
high risk/ER-negative BC patients who received adjuvant-ACT.
Patients whose tumour was found to be HAGEþ and received
adjuvant-ACT (n¼ 141) exhibited a similar risk of death,
recurrence and distant metastases to those whose tumour was
HAGE (Figure 4C). This suggests a beneficial effect of ACT.
PLA-BC patients treated with neo-adjuvant ACT (n¼ 196). To
validate the previous observation regarding the effect of HAGE
expression and response to ACT, we investigated its expression in
PLA-BC patients treated with neoadjuvant-ACT. All patients
received neo-adjuvant-ACT, 63% (123 out of 196) without and
37% (73 out of 196) with Taxane (Supplementary Table S3). Sixty-
three percent of patients received six cycles of FEC (5-fluorouracil
500mg 2, epirubicin 75–100mg 2, cyclophosphamide 500mg 2,
on day 1 of a 21-day cycle).
Thirteen percent (26 out of 196) of PLA-BC patients achieved
pCR. The rates of pCR were higher for TNBC (26%; 14 out of 55)
and the ER /PR /HER2þ subtypes (19%; 3 out of 16) than for
the ERþ /PRþ /HER2 (8%; 8 out of 104) and ERþ /PRþ /
HER2þ (5%; (1 out of 21) subtypes; P¼ 0.009).
High prechemotherapy TIL scores were more frequent in the
ER /PR /HER2þ (31%; 5 out of 16) and TNBC (27%; 15 out of 55)
subtypes than in the ERþ /PRþ /HER2þ (19%; 4 out of 21)
and ERþ /PRþ /HER2 (11%; 11 out of 104) subtypes
(P¼ 0.029). Postchemotherapy surgical specimens of TNBC
subtypes showed higher TIL (31%; 17 out of 55) compared with
ER /PR /HER2þ (12.5%; 2 out of 16), ERþ /PRþ /
HER2þ (9.5%; 2 out of 21) and ERþ /PRþ /HER2 (11.5%; 12
out of 104) subtypes (P¼ 0.012). A high prechemotherapy TIL
score was significantly associated with prechemotherapy HAGEþ
expression (P¼ 0.018).
Prechemotherapy TILs and HAGE expression are independent
predictors of pCR rate for neoadjuvant-ACT. Among the 167
prechemotherapy core biopsies from patients with PLA-BC, 47%
(78 out of 167) were HAGEþ , and of those 24% (19 out of 78)
achieved pCR. Tumours with prechemotherapy TILþ achieved
higher pCR rates (40%) compared with those with a TIL status
(7.5%); Po0.0001. Sixty-five percent of prechemotherapy TILþ /
HAGEþ tumours achieved pCR, and the remaining 35% were
HAGE in postchemotherapy specimens (Po0.0001). In contrast,
only 25, 16 and 6% of the prechemotherapy TILþ /HAGE ,
TIL /HAGEþ and TIL /HAGE tumours achieved pCR,
respectively (Po0.0001). Of note was the observation that 51%
of prechemotherapy TIL /HAGEþ tumours were found to be
HAGE after receiving neoadjuvant chemotherapy. A statistically
significant loss of HAGE expression following neoadjuvant
chemotherapy was found among the 106 cases that were
HAGE– (n =764)
HAGE+ (n =68)
Log rank=45.4, P =2×10–11
High-risk ER–ER+ endocrine therapy
Clinical outcome of the test set
Whole set Lymph node negative
HAGE– (n =472)
HAGE+ (n =42)
Log rank=60.6, P = 7×10–15
HAGE– (n =165)
HAGE+ (n =29)
Log rank=8.0, P =0.005
HAGE– (n =224)
HAGE+ (n =15)
Log rank=8.9, P =0.003
HAGE– (n =764)
HAGE+ (n =68)
Log rank=23.9, P =0.000001
Breast cancer-specific survival (months)
HAGE– (n =224)
HAGE+ (n =15)
Log rank=4.7, P = 0.030
Breast cancer-specific survival (months)
HAGE– (n =472)
HAGE+ (n =42)
Log rank=35.4, P = 3×10–9
Breast cancer-specific survival (months)
HAGE+ (n =29)
Breast cancer-specific survival (months)
Log  rank=11.9, P = 0.001
Disease-free survival (months)Disease-free survival (months)Disease-free survival (months)Disease-free survival (months)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
Cu
m
 s
ur
viv
al
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
 s
ur
viv
al
0.
00
12
.0
0
24
.0
0
36
.0
0
48
.0
0
60
.0
0
72
.0
0
84
.0
0
96
.0
0
10
8.
00
12
0.
00
13
2.
00
14
4.
00
15
6.
00
16
8.
00
18
0.
00
19
2.
00
20
4.
00
21
6.
00
22
8.
00
24
0.
00
25
2.
00
HAGE– (n =165)
A B C D
Figure 2. The clinical outcome of HAGE protein expression in the test set of primary early breast cancer (PE-BC). Kaplan–Meier curves showing
the relationship between HAGE expression and breast cancer-specific survival and disease-free survival in the test set of primary early breast
cancer (PE-BC). (A) Whole cohort; (B) LN ; (C) ERþ ; (D) high-risk ER subpopulation. See text for details.
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paired prechemotherapy and postchemotherapy, (P¼ 0.000001;
Supplementary Table 5).
Multivariate logistic regression analysis showed that
prechemotherapy TIL status (OR (95% CI)¼ 5.9 (1.8–20.8),
P¼ 0.005) and HAGE expression (OR (95% CI)¼ 4.6 (1.3–16.4),
P¼ 0.021) are independent predictors of pCR in patients with
PLA-BC (Table 3).
Clinical outcome of HAGE expression and TILs status in
PLA-BC. Patients with PLA-BC who received neoadjuvant-ACT
and exhibited high levels of HAGE expression before chemotherapy
exhibited a risk of progression which was similar to that in PLA-BC
patients expressing low/no HAGE (log rank; 1.3, P¼ 0.250,
Figure 5(A-1)). However, ER BC patients who received
neoadjuvant ACT and exhibited HAGEþ expression before
chemotherapy were at a lower risk of progression than in those
with HAGE expression (log rank; 3.89, P¼ .049, Figure 5(A-2)).
In contrast, patients with HAGEþ residual disease after
neoadjuvant-ACT exhibited a worse progression-free survival
(log rank; 12.8, P¼ 0.0003) than those in whom HAGE expression
was absent (Figure 5(B-1)). This was especially the case for patients
with ERþ tumours (log rank; 7.6, P¼ 0.006); Figure 5(B-2).
High prechemotherapy TIL status was significantly associated
with increased BCSS (HR, 0.07; 95% CI, 0.01 to 0.51; P¼ 0.009)
and DFS (HR, 0.05; 95% CI, 0.01 to 0.36; P¼ 0.003), whereas high
postchemotherapy TIL status was associated with increases in DFS
(HR, 0.43; 95% CI, 0.19 to 0.94; P¼ 0.033) and a trend towards an
increased BCSS (HR, 0.41; 95% CI, 0.16 to 1.05; P¼ 0.062).
The 5-year DFS rates for the high prechemotherapy TILsþ /
HAGEþ (90%) and TILsþ /HAGE (86%) subgroups were
higher than for those with TILs /HAGEþ (53%) and TILs /
HAGE (46%); P¼ 0.001.
DISCUSSION
To the best of our knowledge, this is the first study to report on the
prognostic and predictive values of HAGE expression in primary BC.
The clinically significant findings of this study are that:
(a) HAGEþ expression is significantly associated with aggressive
clinico-pathological and high proliferation parameters and acts as a
novel independent factor for poor prognosis; (b) HAGEþ expression
identifies a subgroup of PER-BC and PERþBC patients who could
benefit from ACT and are resistant to tamoxifen; respectively; and
(c) TILs and HAGEþ expression in prechemotherapy biopsies are
independent predictors of pCR of PLA-BC. Because of the high level
of HAGE protein expression in tumours compared with normal
tissues, its association with lymphocyte infiltration and the previously
reported immunogenic potential of HAGE (Mathieu et al, 2007), this
antigen could be proposed as a novel immunotherapeutic target for
this sub-group of BC patients with HAGEþ (Mathieu et al, 2010).
Work is currently ongoing to confirm that HAGE-specific T cells can
indeed kill HAGE-positive BC cells.
In the current study, high levels of HAGE expression was
observed in 8–10% of patients with BC and was associated with
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Figure 3. The effect of Tamoxifen treatment on the clinical outcome of HAGE protein expression in high risk oestrogen receptor positive (ERþ )
primary early breast cancer (PE-BC). (A, B) Kaplan–Meier curves showing the effect of tamoxifen on breast cancer-specific survival (BCSS) and
disease-free survival (DFS) in high-risk primary ERþ breast cancer, stratified according to the HAGE status. (A) HAGE negative and (B) HAGE
positive. See text for details.
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increased risk of recurrence and metastases. Moreover, an increase
in the percentage of HAGE-positive tumours was found between
early and locally advanced disease. These findings, along with our
previously published data (Linley et al, 2012), support the concept
that HAGE is implicated in the progression of the disease by
driving cell proliferation and potentially the metastasis of BC cells.
HAGE has been shown to be overexpressed at both the mRNA and
protein level at varying frequencies in different human tumours
(Martelange et al, 2000; Adams et al, 2002; Mathieu et al, 2010)
compared with matched normal tissue, with the exception of testes.
Furthermore, in agreement with previous studies on other CTA
(Kurashige et al, 2001; Otte et al, 2001; Yakirevich et al, 2003;
Lurquin et al, 2005; Roman-Gomez et al, 2007; Chen et al, 2011b),
we have found that HAGEþ expression was associated with TNT,
less-differentiated, higher-grade tumours and poorer clinical
outcome. However, the exact molecular mechanisms underlying
the increase of HAGE expression in human cancer remain unclear.
There is substantial evidence that epigenetic events represent
one mechanism that regulates the expression of HAGE, and global
DNA methylation seems to have a major role (Roman-Gomez et al,
2007). It has previously been shown that hypomethylation of the
HAGE gene promoter correlates with increased HAGE expression
and is strongly associated with advanced disease and poor
prognosis of leukaemia. This supports the potential role of HAGE
in increased cellular proliferation and its potential as a marker of
disease progression (Roman-Gomez et al, 2007). Interestingly, the
global hypomethylation of DNA and histones has been shown to
progressively increase in parallel with advanced grade and disease
progression in human cancers (Kim et al, 1994; Qu et al, 1999;
Soares et al, 1999; Piyathilake et al, 2001).
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Figure 4. The clinical outcome of HAGE protein expression in high risk oestrogen receptor negative (ER-) primary early breast cancer (PE-BC).
(A–C) Kaplan–Meier curves showing the relationship between HAGE expression and breast cancer-specific survival (BCSS) and disease-free survival
(DFS) in primary oestrogen receptor-negative breast cancer (PER-BC), stratified according to the received adjuvant chemotherapy protocols.
(A) Whole cohort, (B) no chemotherapy/or less effective CMF and (C) anthracycline combination therapy (ACT). See text for details.
Table 3. Multivariate regression analysis
Factors OR 95% CI P
Tumour-infiltrating lymphocyte(TILþ ) 5.92 1.69–20.78 0.005a
Prechemotherapy HAGE (þ ) 4.55 1.26–16.44 0.021a
Top2A (þ ) 4.53 1.10–18.88 0.038a
Triple negative (þ ) 3.1 0.84–11.46 0.091
Clinical TNM stage (II vs III) 0.97 0.22–4.25 0.964
Tumour grade (G1/2 vs G3)** 0.4 0.13–1.25 0.114
Maximum diameter of prechemotherapy
tumour size (continuous)
1.01 0.99–1.04 0.422
Patient age (continuous) 1.03 0.96–1.09 0.426
Abbreviations: CI¼ confidence interval; HAGE¼helicase antigen; OR¼odds ratio; TNM¼
Tumour, Node, Metastases; TOP2A¼ topoisomerase (DNA) II alpha. TIL, HAGE and TOP2A
are independent predictors for pathological complete response. **Nottingham histological
grading system.
aStatistically significant.
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The precise function of HAGE in human cancer remains
unknown. We have recently confirmed that HAGE is involved in
promoting proliferation via the Ras signalling pathway. This was
illustrated by observations that transfection of cells with a HAGE
cDNA construct increased cell proliferation of cells and that the
silencing of HAGE reduced proliferation (Linley et al, 2012).
Moreover, preliminary results using shRNA to permanently knock
down HAGE expression also suggest the involvement of HAGE in
tumour motility and metastasis (data not shown). Roman-Gomez
et al (2007) have speculated that HAGE expression might confer a
selective advantage over HAGE cells in blast crisis in leukaemia.
Although this would explain the selection of HAGEþ cells during
the progression of leukaemia, the possible role of HAGE in the
transformed status of BC cells needs to be clarified in further
functional studies.
In the present study, survival analysis indicates that HAGE
is an independent prognostic factor for EP-BC patients. This
finding is consistent with the finding in leukaemia, in which
HAGEþ transcripts have been associated with poor prognosis
(Roman-Gomez et al, 2007; Chen et al, 2011a). Similarly, for a
given cancer type, higher expression of some other CTAs,
such as testes-specific protease 50 (TSP 50) for colorectal
(Zheng et al, 2011), MAGE-A3 for pancreatic cancer
(Kim et al, 2006), MAGE-C2 for hepatocellular carcinoma
(Riener et al, 2009) and NY-ESO-1 for malignant melanoma
(Velazquez et al, 2007), were often correlated with poorer
outcomes. Recently, Germain et al (2011) found that expression
of DEAD-box 1 mRNA is an independent prognostic marker for
the early recurrence of BC.
The protein encoded by the HAGE gene is a member of the
family of ‘DEAD-box proteins’, which function as important
transcriptional regulators and are involved in many aspects of
RNA metabolism, spermatogenesis, embryogenesis and cell growth
(Iggo et al, 1990; Yang et al, 2005; Roman-Gomez et al, 2007). The
DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have
been shown to act as transcriptional co-activators for a diverse
range of transcription factors, including oestrogen receptor a
(ERa), and a role for them in miRNA maturation, ribosome
biogenesis, mRNA splicing and insulator function have also been
described (Shin et al, 2007; Wortham et al, 2009). IHC staining of
ERa-positive primary BC for these DEAD-box proteins indicated
that p72 expression was associated with prolonged DFS and OS as
well as being inversely associated with HER2 expression. Our
studies have found HAGEþ expression to be associated with ER-
negative expression and other aggressive phenotypes, such as
TNBC, HER2 overexpression, proliferation and high grade.
Furthermore, HAGEþ expression was associated with DFS and
BCSS and tamoxifen residence in ERþ tumours. However, further
functional studies to confirm these preliminary data are warranted.
HAGE expression could prove to be a useful biomarker in the
stratification of patients with BC for chemotherapy, as our data
show that HAGEþ patients may benefit from ACT. It can be
postulated that cells expressing HAGE proliferate faster and are
therefore more responsive to ACT. A recent study (Zheng et al,
2011) has shown that cell proliferation, colony formation, migration
and cell apoptosis were reduced/inhibited and cell sensitivity to
doxorubicin enhanced, when the TSP50 gene expression was
silenced. Moreover, the fact that patients with HAGEþ residual
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Figure 5. The clinical outcome of HAGE protein expression in primary locally advanced breast cancer (PLA-BC) before and after receiving
neoadjuvant chemotherapy. (A) Kaplan–Meier curves illustrating the relationship between prechemotherapy expression of HAGE and disease-free
survival (DFS) in the entire PLA-BC cohort (A-1) and in the ER subgroup (A-2). (B) Kaplan–Meier curves illustrating the relationship between
HAGE expression and DFS in patients who exhibited evidence of pathological residual disease after receiving neoadjuvant-ACT in the entire
PLA-BC cohort (B-1) and in the ERþ subgroup (B-2).
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disease (ACT-resistant cells) exhibited a poorer outcome suggests
that alternative therapy such as immunotherapy may be warranted
for this group. Zitvogel et al (2008) have highlighted that
anthracyclines, unlike many other cytotoxic agents, can elicit
immunogenic cell death and potentiate the potency of vaccines.
The DNA methyltransferase inhibitor 5-aza-20-deoxycytidine
(decitabine) has been shown to be beneficial for patients with
chronic myeloid leukaemia (Issa et al, 2004). Drugs that are
capable of inducing HAGE expression could therefore increase the
eligibility of patients for CTA-targeted immunotherapy and
improve the management of patients with recurrent disease.
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